The Effect of Community Pharmacist Prescribing and Care on Cardiovascular Risk Reduction: The RxEACH Multicentre Randomized Controlled Trial
- At: 2016 FIP Congress in Buenos Aires (Argentina)
- Type: Presentation
- By: TSUYUKI, Ross (Faculty of Medicine and Dentistry, University of Alberta, Department of Medicine/Cardiology, Edmonton, Canada)
- Co-author(s): Ross Tsuyuki:|Yazid Al Hamarneh:Medicine/Cardiology,University of Alberta,Edmonton,Canada|Charlotte Jones:Medicine,Southern Medical Program, University of British Columbia,Kelowna,Canada|Brenda Hemmelgarn:Community Health Sciences/Medicine,University of Calgary,Calgary,Canada
The cardiovascular disease (CVD) risk factors hypertension, diabetes, dyslipidemia, and smoking remain poorly identified and controlled.
RxEACH was a per patient randomized controlled trial conducted in 56 community pharmacies in Alberta, Canada.
Population: High risk adults with diabetes, chronic kidney disease, vascular disease, or Framingham.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.